We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Efp4.3
Efpeglenatide Research
Mostly mechanism / observational
23 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Efpeglenatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2019–2026 with a typical study size of 4,059 participants.
Based on 23 studies · 8 meta-analyses · 10 RCTs · 426,551 total participants
Confidence
High confidence
By outcome
Glycemic controlDose-dependent HbA1c reductions across the program; pooled meta-analysis HbA1c -0.84% vs placebo · Weeks to months
Mostly mechanism / observational22 studies
Weight & body compositionIn obesity without diabetes, placebo-adjusted weight loss of ~6.3-7.2 kg over 20 weeks (phase-2) · Months (titrated)
Mostly mechanism / observational10 studies
Cardiovascular & renal outcomesAMPLITUDE-O reduced the primary MACE composite by 27% vs placebo (HR 0.73) in high-risk type 2 diabetes · Over ~1.8 years
Mostly mechanism / observational10 studies
Safety profile
Mostly mechanism / observational6 studies
Active research area
19 studies in the last 5 years · Latest meta-analysis: 2025
In plain English: Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis]; CRD420251032222).
Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. · Journal of the American College of Cardiology (2025)
We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls.
GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders.
Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.
In plain English: Further research is warranted to elucidate the molecular pathways underlying its anti-metastatic properties and to explore its role in preventive oncology.
Hsu CW, Zeng BS, Liang CS, Zeng BY, Hung CM, Stubbs B, Chen YW, Lei WT, Chen JJ, Chen PH, Su KP, Chen TY, Tseng PT. · International journal of molecular sciences (2025)
This NMA of 207,606 participants from 67 RCTs revealed that only efpeglenatide demonstrated a statistically significant reduction in metastatic cancer events compared to controls (odds ratio = 0.26, 95% confidence intervals = 0.09 to 0.70, p = 0.010, number needed to treat = 188.4).
Efpeglenatide's efficacy was not confined to specific cancer types.
Safety profiles were comparable across all treatments.
In plain English: In conclusion, efpeglenatide is a promising treatment for T2DM and obesity, offering effective glycemic control, weight reduction, cardiovascular and renal benefits, a favorable safety profile, and convenient dosing.
Narayan N, Vadde T, Sandesara M, Divity S, Mamytova A, Tagaev T. · Cureus (2025)
The findings of these studies consistently indicate that efpeglenatide significantly reduces hemoglobin A1C (HbA1C), fasting plasma glucose (FPG), and body weight in patients with T2DM and obesity.
Most studies show a low risk of bias and enhanced reliability.
However, limitations include the need for long-term safety data and variations in study design.
In plain English: The profound biochemical and weight loss outcomes associated with incretin co-/poly-agonists are expected to translate into outstanding cardiometabolic benefits, the theme of this evidence review.
Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM. · World journal of cardiology (2025)
Other drugs of the same group in development include Orforglipron, which has a high weight loss efficacy (-15% weight reduction).
The revolutionary triple agonists at the GLP-1, GIP, and Glucagon receptors have demonstrated the highest achievable weight loss with pharmacotherapy.
Retatrutide and Efocipegtrutide belong to this novel group of drugs.
In plain English: These findings provide a structured evidence map to inform future consensus and clinical decision-making.
Rico-Fontalvo J, Daza-Arnedo R, Elbert A, Correa-Rotter R, Dina-Batlle E, Lorca-Herrera E, de Moraes TP, Sánchez-Polo V, Builes-Montaño CE. · Diabetes therapy : research, treatment and education of diabetes and related disorders (2026)
Across agents, renal benefits were partly independent of glycemic and weight effects.
Conclusion GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes.
Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents.
In plain English: Future large-scale, high-quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients.
An X, Sun W, Wen Z, Duan L, Zhang Y, Kang X, Ji H, Sun Y, Jiang L, Zhao X, Gao Q, Lian F. · Diabetes, obesity & metabolism (2025)
GLP-1RAs did not significantly increase the incidence of adverse events, but Orforglipron and Taspoglutide significantly increased the incidence of gastrointestinal adverse events compared with placebo.
Conclusion This study compared the cardiovascular benefits of different GLP-1RAs, including reductions in cardiovascular events and improvements in multiple cardiovascular risk factors.
However, due to limitations in the quantity and quality of the included studies, the conclusions should be interpreted with caution.
In plain English: The beneficial effect of efpeglenatide on these outcomes is independent of FIB-4 category.
Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC. · Cardiovascular diabetology (2024)
Results Baseline FIB-4 score was available for 4059 participants (99.6%) allowing subdivision of the population in tertiles.
During a median follow-up of 1.8 years, numerical increases in the incidence of all 3 outcomes did not change significantly across tertiles of FIB-4 score (P for trend ≥ 0.25) with negligible relationship of the score to incident outcomes (MACE HR, per 1 SD higher score, 95% CI: 1.00, 0.89-1.13).
Efpeglenatide's effect on all MACE outcomes did not vary across FIB-4 tertiles (all interaction p values ≥ 0.64).
18Systematic Reviewn=83,215 · very large study2026
In plain English: Overall, these findings support guideline-based use of GLP-1 RAs in high-risk T2D while highlighting the need for individualized treatment selection.
Abomohsen M, Rifai M, Gadelmawla AF, Alghzawi HM, Elgendy MS, Bakr HM, Friedman A, Idries IY. · Canadian journal of diabetes (2026)
We conducted a frequentist random-effects network meta-analysis and reported risk ratios (RRs) with 95% confidence intervals (CIs).
In the 3-point major adverse CV event (MACE) network (11 trials, 11 regimens), heterogeneity and inconsistency were absent (I 2 =0%, τ 2 =0).
MACE rate was reduced with subcutaneous semaglutide (RR 0.74, 95% CI 0.58 to 0.94), efpeglenatide (0.76, 0.61 to 0.94), and albiglutide (0.79, 0.69 to 0.91); tirzepatide, oral semaglutide, liraglutide, and dulaglutide were also significantly reduced compared with placebo.
In plain English: All efpeglenatide doses ≥1 mg significantly reduced HbA1c versus placebo (placebo-adjusted least squares [LS] mean changes 0.6-1.2%, P < 0.05 for all)... masked efpeglenatide 4 mg was noninferior to open-label liraglutide.
Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KH. · Diabetes Care (2019)
Phase-2 'EXCEED 203' 12-week randomized, double-blind, placebo-controlled dose-ranging study in early type 2 diabetes (drug-naive or on metformin), referenced to open-label liraglutide 1.8 mg (exploratory)
All efpeglenatide doses ≥1 mg lowered HbA1c by a placebo-adjusted 0.6-1.2% to a final HbA1c of 6.3-6.8%; the 4 mg dose was noninferior to liraglutide
Greater weight loss with 3 and 4 mg vs placebo (placebo-adjusted -1.4 and -2.0 kg); no neutralizing antibodies detected
In plain English: Direct meta-analysis showed significant WLOP with... -3.20kg (-6.53 to 0.15) with efpeglenatide... -9.88kg (-13.17 to -6.59) with semaglutide SQ 2.4mg... Highest WLOP were with semaglutide SQ 2.4mg and <2.4mg, and liraglutide >1.8mg.
Vosoughi K, Atieh J, Khanna L, Khoshbin K, Prokop LJ, Davitkov P, Murad MH, Camilleri M. · EClinicalMedicine (2021)
Systematic review and frequentist network meta-analysis of 64 RCTs (n=27,018) comparing 7 GLP-1 agents on weight loss and adverse events in obesity
Efpeglenatide's weight-loss-over-placebo point estimate was ~-3.2 kg, placing it within the class but below high-dose semaglutide and liraglutide
Semaglutide 2.4 mg gave the largest weight loss (~-9.9 kg over placebo); discontinuation due to AEs was highest with taspoglutide and high-dose liraglutide